<DOC>
	<DOCNO>NCT01419704</DOCNO>
	<brief_summary>The goal research study establish chimerism avoid graft-versus-host disease patient hemoglobinopathy .</brief_summary>
	<brief_title>Phase I/II Pilot Study Mixed Chimerism Treat Hemoglobinopathies</brief_title>
	<detailed_description>This proposal phase I/II feasibility study demonstrate mixed chimerism establish minimal risk recipient hemoglobinopathy treat Campath-1H-based nonmyeloablative conditioning graft engineering reduce risk Graft Versus Host Disease ( GVHD ) , preserve engraftment donor cell .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>alpha-Thalassemia</mesh_term>
	<criteria>1 . Inclusion Criteria The following criterion establish identify subject hemoglobinopathy , hematologic bone marrow failure syndromes high predict morbidity risk early mortality : Patients alpha beta thalassemia major . Patients DiamondBlackfan anemia bone marrow failure syndrome , characterize severe chronic anemia . Patients complex transfusiondependent hemoglobinopathy , include sickle cell disease . Patients sickle disease one following : Overt silent stroke Neurocognitive impairment Pain crises 2 episode per year past year One episodes acute chest syndrome Osteonecrosis involve 1 joint Evidence retinopathy Priapism Microalbuminuria evidence sickle cell nephropathy Alloimmunization Subjects must also meet follow general inclusion criterion : Subjects must relate donor consist Histocompatibility Leukocyte Antigen ( HLA ) match donor haploidentical match , mismatch 1 , 2 3 HLAA , B DR locus . Subjects must adequate cardiopulmonary function document echocardiogram radionuclide scan . ( Shortening fraction &gt; 26 % ejection fraction &gt; 40 % ≥ 80 % normal value age ) . Subjects must adequate pulmonary function document Forced expiratory volume 1 second ( FEV1 ) ≥ 50 % predict age and/or Diffusing capacity lung carbon monoxide ( DLCO ) ( correct hemoglobin ) ≥50 % predicted age patient &gt; 10 year age . Subjects must adequate hepatic function demonstrate serum albumin ≥ 3.0 mg/dL , serum glutamic pyruvic transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) less equal 5 time upper limit normal . Liver biopsy liver MRI necessary patient receive chronic transfusion year and/or ferritin level ≥ 1600 . Subjects must adequate renal function demonstrate serum creatinine less equal 2 mg/dL . If serum creatinine ≥ 2 mg/dL , creatinine clearance test nuclear medicine GFR document GFR ≥ 50 ml/min/1.73 m2 . Subjects legal guardian must give write informed consent . Female patient childbearing potential pregnant lactating/breastfeeding must either surgically sterile , postmenopausal ( menses previous 12 month ) , must practice effective method birth control determine investigator ( e.g. , oral contraceptive , double barrier method , hormonal injectable implanted contraceptive , tubal ligation , partner vasectomy ) . Less equal 45 year age . 2 . Exclusion Criteria Patients cirrhosis , extensive bridging hepatic fibrosis , active hepatitis exclude enrollment . Uncontrolled infection severe concomitant disease , judgment Principal Investigator , indicate patient could tolerate reduce intensity transplantation . Severe impairment functional performance evidence Karnofsky score &lt; 70 % ( patient ≥16 year old ) Lansky ( child &lt; 16 year old ) score &lt; 70 % Renal insufficiency ( GFR &lt; 50 ml/min/1.73 m2 ) . Subjects positive human immunodeficiency virus ( HIV ) antibody test result . Subjects pregnant , indicate positive serum human chorionic gonadotrophin ( HCG ) test . Subjects whose donor pregnant time intend transplant . Subjects childbearing potential practicing adequate contraception define investigator site . Allogeneic hematopoietic stem cell transplant within previous 1 year . Subjects must previous radiation therapy would preclude total body irradiation ( TBI ) ( determine radiation therapist ) . Jehovah 's Witness unwilling transfuse . Uncontrolled hypersplenism . Severe alloimmunization inability guarantee supply adequate pack red blood cell ( PRBC ) donor . Subjects thalassemia Lucarelli Class 3 Fanconi anemia . Insufficient fund bone marrow processing cost</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemoglobinopathy</keyword>
	<keyword>chimerism</keyword>
	<keyword>sickle cell</keyword>
	<keyword>thalassemia</keyword>
	<keyword>Marrow/Enriched Hematopoetic Stem Cell Transplant</keyword>
</DOC>